{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:14:17Z","timestamp":1790957657408,"version":"4.1.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100006692","name":"University of Turin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006692","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.cld.2023.01.018","type":"journal-article","created":{"date-parts":[[2023,2,26]],"date-time":"2023-02-26T15:17:10Z","timestamp":1677424630000},"page":"239-250","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Extrahepatic Outcomes of Nonalcoholic Fatty Liver Disease"],"prefix":"10.1016","volume":"27","author":[{"given":"Angelo","family":"Armandi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Bugianesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.cld.2023.01.018_bib1","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jhep.2016.09.022","article-title":"Bi-directional analysis between fatty liver and cardiovascular disease risk factors","volume":"66","author":"Ma","year":"2017","journal-title":"J\u00a0Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2023.01.018_bib2","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.atherosclerosis.2013.07.052","article-title":"A\u00a0systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care?","volume":"230","author":"Oni","year":"2013","journal-title":"Atherosclerosis"},{"issue":"5","key":"10.1016\/j.cld.2023.01.018_bib3","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.jhep.2017.12.012","article-title":"Association between non-alcoholic fatty liver disease and subclinical coronary atherosclerosis: an observational cohort study","volume":"68","author":"Lee","year":"2018","journal-title":"J\u00a0Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2023.01.018_bib4","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1002\/hep.22845","article-title":"Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population","volume":"49","author":"Gastaldelli","year":"2009","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.cld.2023.01.018_bib5","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.2337\/dc06-2247","article-title":"Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients","volume":"30","author":"Targher","year":"2007","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.cld.2023.01.018_bib6","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1053\/j.gastro.2016.06.001","article-title":"Persistent nonalcoholic fatty liver disease increases risk for carotid atherosclerosis","volume":"151","author":"Sinn","year":"2016","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.cld.2023.01.018_bib7","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.jhep.2017.07.027","article-title":"Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD","volume":"67","author":"Hagstr\u00f6m","year":"2017","journal-title":"J\u00a0Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2023.01.018_bib8","doi-asserted-by":"crossref","first-page":"e0131138","DOI":"10.1371\/journal.pone.0131138","article-title":"Nonalcoholic hepatic steatosis is a strong predictor of high-risk coronary-artery plaques as determined by multidetector CT","volume":"10","author":"Osawa","year":"2015","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.cld.2023.01.018_bib9","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jhep.2016.05.013","article-title":"Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis","volume":"65","author":"Targher","year":"2016","journal-title":"J\u00a0Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2023.01.018_bib10","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/MEG.0000000000001075","article-title":"Synergistic increase in cardiovascular risk in diabetes mellitus with nonalcoholic fatty liver disease: a meta-analysis","volume":"30","author":"Zhou","year":"2018","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2023.01.018_bib11","doi-asserted-by":"crossref","first-page":"33386","DOI":"10.1038\/srep33386","article-title":"Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: a systematic review and meta-analysis","volume":"6","author":"Wu","year":"2016","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.cld.2023.01.018_bib12","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/hep.27368","article-title":"Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up","volume":"61","author":"Ekstedt","year":"2015","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.cld.2023.01.018_bib13","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/hep.26156","article-title":"Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States","volume":"57","author":"Kim","year":"2013","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.cld.2023.01.018_bib14","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1136\/gutjnl-2021-325724","article-title":"Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort","volume":"71","author":"Simon","year":"2022","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.cld.2023.01.018_bib15","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1053\/j.gastro.2018.04.034","article-title":"Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease: a multi-national cohort study","volume":"155","author":"Vilar-Gomez","year":"2018","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.cld.2023.01.018_bib16","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1136\/heartjnl-2013-305099","article-title":"Non-alcoholic fatty liver disease, metabolic syndrome and subclinical cardiovascular changes in the general population","volume":"100","author":"Kim","year":"2014","journal-title":"Heart"},{"issue":"2","key":"10.1016\/j.cld.2023.01.018_bib17","doi-asserted-by":"crossref","first-page":"E282","DOI":"10.1152\/ajpendo.00604.2005","article-title":"Liver steatosis coexists with myocardial insulin resistance and coronary dysfunction in patients with type 2 diabetes","volume":"291","author":"Lautam\u00e4ki","year":"2006","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.cld.2023.01.018_bib18","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/hep.21983","article-title":"Increased mediastinal fat and impaired left ventricular energy metabolism in young men with newly found fatty liver","volume":"47","author":"Perseghin","year":"2008","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.cld.2023.01.018_bib19","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1002\/hep.26610","article-title":"Left ventricular dysfunction in obese children and adolescents with nonalcoholic fatty liver disease","volume":"59","author":"Pacifico","year":"2014","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.cld.2023.01.018_bib20","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/s41575-018-0010-0","article-title":"Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease","volume":"15","author":"Anstee","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.cld.2023.01.018_bib21","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/liv.14044","article-title":"Association between non-alcoholic fatty liver disease and risk of atrial fibrillation in adult individuals: an updated meta-analysis","volume":"39","author":"Mantovani","year":"2019","journal-title":"Liver Int"},{"issue":"2","key":"10.1016\/j.cld.2023.01.018_bib22","doi-asserted-by":"crossref","first-page":"e57183","DOI":"10.1371\/journal.pone.0057183","article-title":"Non-alcoholic fatty liver disease is associated with an increased incidence of atrial fibrillation in patients with type 2 diabetes","volume":"8","author":"Targher","year":"2013","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.cld.2023.01.018_bib23","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.2337\/dc16-0091","article-title":"Nonalcoholic fatty liver disease is associated with ventricular arrhythmias in patients with type 2 diabetes referred for clinically indicated 24-hour holter monitoring","volume":"39","author":"Mantovani","year":"2016","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.cld.2023.01.018_bib24","doi-asserted-by":"crossref","first-page":"483","DOI":"10.3350\/cmh.2021.0406","article-title":"Non-alcoholic fatty liver disease increases risk of carotid atherosclerosis and ischemic stroke: an updated meta-analysis with 135,602 individuals","volume":"28","author":"Tang","year":"2022","journal-title":"Clin Mol Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2023.01.018_bib25","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1161\/STROKEAHA.120.030433","article-title":"Severity of nonalcoholic fatty liver disease and risk of future ischemic stroke events","volume":"52","author":"Xu","year":"2021","journal-title":"Stroke"},{"issue":"3","key":"10.1016\/j.cld.2023.01.018_bib26","doi-asserted-by":"crossref","first-page":"577-e34","DOI":"10.1111\/ene.13556","article-title":"Non-alcoholic fatty liver disease is associated with stroke severity and progression of brainstem infarctions","volume":"25","author":"Li","year":"2018","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.cld.2023.01.018_bib27","doi-asserted-by":"crossref","first-page":"812030","DOI":"10.3389\/fcvm.2022.812030","article-title":"Association between non-alcoholic fatty liver disease and risk of stroke: a systematic review and meta-analysis","volume":"9","author":"Wang","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.cld.2023.01.018_bib28","doi-asserted-by":"crossref","first-page":"116524","DOI":"10.1016\/j.jns.2019.116524","article-title":"Association between nonalcoholic fatty liver disease with advanced fibrosis and stroke","volume":"407","author":"Parikh","year":"2019","journal-title":"J\u00a0Neurol Sci"},{"key":"10.1016\/j.cld.2023.01.018_bib29","doi-asserted-by":"crossref","first-page":"l5367","DOI":"10.1136\/bmj.l5367","article-title":"Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adults","volume":"367","author":"Alexander","year":"2019","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.cld.2023.01.018_bib30","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1111\/ene.15277","article-title":"Non-alcoholic fatty liver disease and stroke: a Mendelian randomization study","volume":"29","author":"Wu","year":"2022","journal-title":"Eur J Neurol"},{"issue":"20","key":"10.1016\/j.cld.2023.01.018_bib31","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1016\/j.jacc.2018.03.509","article-title":"Epicardial adipose tissue may mediate deleterious effects of obesity and inflammation on the myocardium","volume":"71","author":"Packer","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.cld.2023.01.018_bib32","doi-asserted-by":"crossref","first-page":"984","DOI":"10.3945\/ajcn.117.157115","article-title":"Dynamics of intrapericardial and extrapericardial fat tissues during long-term, dietary-induced, moderate weight loss","volume":"106","author":"Tsaban","year":"2017","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.cld.2023.01.018_bib33","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.3389\/fimmu.2019.02163","article-title":"Adipocytes directly affect coronary artery disease pathogenesis via induction of adipokine and cytokine imbalances","volume":"10","author":"Gruzdeva","year":"2019","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.cld.2023.01.018_bib34","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jacc.2010.02.049","article-title":"Effects of hepatic triglyceride content on myocardial metabolism in type 2 diabetes","volume":"56","author":"Rijzewijk","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.cld.2023.01.018_bib35","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1089\/met.2019.0115","article-title":"High-risk atherosclerosis and metabolic phenotype: the roles of ectopic adiposity, atherogenic dyslipidemia, and inflammation","volume":"18","author":"Lechner","year":"2020","journal-title":"Metab Syndr Relat Disord"},{"issue":"1","key":"10.1016\/j.cld.2023.01.018_bib36","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1124\/pr.114.010090","article-title":"Toll-like receptors in the vascular system: sensing the dangers within","volume":"68","author":"Goulopoulou","year":"2016","journal-title":"Pharmacol Rev"},{"issue":"3","key":"10.1016\/j.cld.2023.01.018_bib37","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3390\/metabo11030155","article-title":"Insulin resistance across the spectrum of nonalcoholic fatty liver disease","volume":"11","author":"Armandi","year":"2021","journal-title":"Metabolites"},{"issue":"4","key":"10.1016\/j.cld.2023.01.018_bib38","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1161\/01.CIR.0000080884.27358.49","article-title":"Relationship of metabolic syndrome and fibrinolytic dysfunction to cardiovascular disease","volume":"108","author":"Anand","year":"2003","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.cld.2023.01.018_bib39","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jhep.2019.09.014","article-title":"Hepatocyte-derived extracellular vesicles promote endothelial inflammation and atherogenesis via microRNA-1","volume":"72","author":"Jiang","year":"2020","journal-title":"J\u00a0Hepatol"},{"issue":"12","key":"10.1016\/j.cld.2023.01.018_bib40","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/ng.257","article-title":"Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease","volume":"40","author":"Romeo","year":"2008","journal-title":"Nat Genet"},{"issue":"4","key":"10.1016\/j.cld.2023.01.018_bib41","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1002\/hep.23622","article-title":"Homozygosity for the patatin-like phospholipase-3\/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease","volume":"51","author":"Valenti","year":"2010","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.cld.2023.01.018_bib42","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/ng.2926","article-title":"Systematic evaluation of coding variation identifies a candidate causal variant in TM6SF2 influencing total cholesterol and myocardial infarction risk","volume":"46","author":"Holmen","year":"2014","journal-title":"Nat Genet"},{"issue":"4","key":"10.1016\/j.cld.2023.01.018_bib43","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1053\/j.gastro.2015.01.038","article-title":"TM6SF2: catch-22 in the fight against nonalcoholic fatty liver disease and cardiovascular disease?","volume":"148","author":"Kahali","year":"2015","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.cld.2023.01.018_bib44","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00125-019-05024-3","article-title":"Non-alcoholic fatty liver disease and cardiovascular disease: assessing the evidence for causality","volume":"63","author":"Brouwers","year":"2020","journal-title":"Diabetologia"},{"issue":"6","key":"10.1016\/j.cld.2023.01.018_bib45","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.3390\/nu13061977","article-title":"Beyond the paradigm of weight loss in non-alcoholic fatty liver disease: from pathophysiology to novel dietary approaches","volume":"13","author":"Armandi","year":"2021","journal-title":"Nutrients"},{"issue":"5","key":"10.1016\/j.cld.2023.01.018_bib46","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1053\/j.gastro.2012.01.034","article-title":"A\u00a0high-fat diet is associated with endotoxemia that originates from the gut","volume":"142","author":"Pendyala","year":"2012","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.cld.2023.01.018_bib47","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1038\/s41467-019-09455-9","article-title":"A\u00a0gut microbiome signature for cirrhosis due to nonalcoholic fatty liver disease","volume":"10","author":"Caussy","year":"2019","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.cld.2023.01.018_bib48","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1186\/s12864-019-6251-7","article-title":"Changes of intestinal bacterial microbiota in coronary heart disease complicated with nonalcoholic fatty liver disease","volume":"20","author":"Zhang","year":"2019","journal-title":"BMC Genomics"},{"issue":"1","key":"10.1016\/j.cld.2023.01.018_bib49","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1172\/JCI94601","article-title":"l-Carnitine in omnivorous diets induces an atherogenic gut microbial pathway in humans","volume":"129","author":"Koeth","year":"2019","journal-title":"J\u00a0Clin Invest"},{"issue":"39","key":"10.1016\/j.cld.2023.01.018_bib50","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1093\/eurheartj\/ehx342","article-title":"Gut microbe-generated metabolite trimethylamine-N-oxide as cardiovascular risk biomarker: a systematic review and dose-response meta-analysis","volume":"38","author":"Schiattarella","year":"2017","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.cld.2023.01.018_bib51","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1161\/ATVBAHA.119.313414","article-title":"Trimethylamine-N-Oxide promotes vascular calcification through activation of NLRP3 (Nucleotide-Binding domain, leucine-rich-containing family, pyrin domain-containing-3) inflammasome and NF-\u03baB (nuclear factor \u03baB) signals","volume":"40","author":"Zhang","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"10.1016\/j.cld.2023.01.018_bib52","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.cell.2016.02.011","article-title":"Gut microbial metabolite TMAO enhances platelet hyperreactivity and thrombosis risk","volume":"165","author":"Zhu","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.cld.2023.01.018_bib53","doi-asserted-by":"crossref","first-page":"19076","DOI":"10.1038\/srep19076","article-title":"Associations of gut-flora-dependent metabolite trimethylamine-N-oxide, betaine and choline with non-alcoholic fatty liver disease in adults","volume":"6","author":"Chen","year":"2016","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.cld.2023.01.018_bib54","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1111\/j.1478-3231.2011.02753.x","article-title":"The Framingham risk score and heart disease in nonalcoholic fatty liver disease","volume":"32","author":"Treeprasertsuk","year":"2012","journal-title":"Liver Int"},{"issue":"6","key":"10.1016\/j.cld.2023.01.018_bib55","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease","volume":"64","year":"2016","journal-title":"J\u00a0Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2023.01.018_bib56","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/CIR.0000000000000510","article-title":"Dietary fats and cardiovascular disease: a presidential advisory from the American heart association","volume":"136","author":"Sacks","year":"2017","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.cld.2023.01.018_bib57","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.cgh.2017.04.039","article-title":"Statin use and risk of cirrhosis and related complications in patients with chronic liver diseases: a systematic review and meta-analysis","volume":"15","author":"Kim","year":"2017","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326123000181?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326123000181?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T17:59:03Z","timestamp":1761069543000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326123000181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":57,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S1089326123000181"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2023.01.018","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Extrahepatic Outcomes of Nonalcoholic Fatty Liver Disease","name":"articletitle","label":"Article Title"},{"value":"Clinics in Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cld.2023.01.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}